Twenty Years Later, “AL Amyloidoma” Not “Non‐Mutated ApoA1”: Enhanced Diagnosis Through Mass Spectrometry Advancement
- 24 April 2025
- journal article
- Published by Wiley in Muscle & Nerve
- Vol. 72 (1) , 168-171
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- The C-Brace® microprocessor controlled stance and swing orthosis improves safety, mobility, and quality of life at one year: Interim results from a prospective registryJournal of Rehabilitation and Assistive Technologies Engineering, 2024
- Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 CasesMayo Clinic Proceedings, 2022
- Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 SamplesMayo Clinic Proceedings, 2020
- Screening Method for M-Proteins in Serum Using Nanobody Enrichment Coupled to MALDI-TOF Mass SpectrometryClinical Chemistry, 2016
- Mass spectrometry analysis reveals non-mutated apolipoprotein a1 lumbosacral radiculoplexus amyloidomaMuscle & Nerve, 2012
- Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathyAnnals of Neurology, 2001